Archive · 3 Oct 2025
AstraZeneca Receives Approval for Cancer Therapy in India
AstraZeneca, a drug company, got permission to sell a cancer medicine called Enhertu in India for more patients.
This medicine is for adults with a specific type of cancer that has spread.
The company's performance was strong, with profits and sales going up in the last quarter.
The company's profits jumped significantly and their revenue also increased.
This means they're selling more and making more money.
The shares of AstraZeneca Pharma India Ltd also increased.
AstraZeneca Pharma India received approval to market Enhertu in India.
The drug is for HER2-positive solid tumors.
Approval allows the import, sale, and distribution of Enhertu.
The company reported a sharp increase in net profit for Q4.
Revenue for Q4 also saw a substantial increase.
- Who
- AstraZeneca Pharma India Limited
- What
- Received approval to market cancer therapy Enhertu in India for additional indications.
- When
- Approval received on or before October 3rd.
- Where
- India
- Why
- To treat adult patients with unresectable or metastatic HER2-positive solid tumors.
- Company
- AstraZeneca Pharma India Limited
- Drug Name
- Enhertu (trastuzumab deruxtecan)
- Approval Agency
- CDSCO
- Indication
- HER2-positive (IHC3+) solid tumors
- Approval Purpose
- Marketing in India
- Q4 Net Profit
- ₹58.2 crore (up 47.7%)
- Q4 Revenue
- ₹480.4 crore (up 25.4%)